In a recent phase II trial, the combination of tiragolumab and atezolizumab demonstrated enhanced objective response rates for patients battling persistent or recurrent PD-L1-positive cervical cancer after undergoing one or two chemotherapy treatments.
Study Overview
The open-label, randomized SKYSCRAPER-04 trial enrolled participants with PD-L1-positive recurrent or persistent cervical cancer, defined by SP263 tumor area positivity of 5% or higher. Patients were assigned in a 3:1 ratio to receive either atezolizumab alone or in combination with tiragolumab every three weeks. The primary goal was to assess the confirmed objective response rate as per RECIST v1.1 criteria compared to historical data.
Key Findings
Results indicated that 19.0% of patients receiving the combination therapy achieved an objective response, compared to 15.6% with atezolizumab alone. The study also noted improved response rates among patients with higher PD-L1 expression levels. Progression-free survival averaged 2.8 months for the combination group versus 1.9 months for the single-agent group. Additionally, overall survival reached 11.1 months with the combination therapy compared to 10.6 months with atezolizumab alone.
• The combination therapy showed a higher objective response rate than the historical benchmark.
• Patients with PD-L1 high expression experienced better outcomes.
• Safety profiles were comparable between the combination and single-agent groups, with minimal severe adverse events.
While the combination of tiragolumab and atezolizumab did not achieve statistical significance in improving response rates, the numerical increase suggests potential benefits for specific patient subgroups.
Future research should focus on identifying biomarkers that predict response to this immunotherapy combination, optimizing patient selection to enhance efficacy, and exploring long-term outcomes to establish the full clinical utility of tiragolumab and atezolizumab in managing recurrent cervical cancer.
This study highlights ongoing efforts to refine second and third-line treatments for cervical cancer, underscoring the importance of personalized medicine in improving patient prognosis and quality of life.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
